Effects of prostacyclin (PGI₂), PGI₁ and 6-oxo-PGF_{1 α} on the rat gastric mucosa

N.K. BOUGHTON-SMITH, J.R. VANE & B.J.R. WHITTLE

Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS

Prostacyclin (PGI₂) is an unstable potent vasodilator, which can be formed by vascular tissue and the rat stomach (Gryglewski, Bunting, Moncada, Flower & Vane, 1976). We have now investigated the effects of PGI₂, its stable degradation product 6-oxo-PGF_{1 α} and 6 β -PGI₁, a 5,6-dihydro prostacyclin (Johnson, Lincoln, Thompson, Nidy, Mizsak & Axen, 1977) on the rat gastric mucosa.

The inhibition of pentagastrin (0.5 μ g kg⁻¹min⁻¹)induced gastric acid secretion and the change in mucosal blood flow (MBF) in the urethaneanaesthetised rat was determined as previously described (Main & Whittle, 1973). PGI, (0.25-5 µg kg-1min-1 i.v.) caused a dose-dependant fall in systemic arterial blood pressure and inhibition of acid output; the ID₅₀ (dose causing 50% inhibition) was 0.5 μg kg⁻¹min⁻¹ (infused i.v. for 30 min) compared with an ID₅₀ of 1 µg kg⁻¹min⁻¹ for PGE₂. Subcutaneous administration of PGI₂ (50-200 µg/kg) likewise inhibited acid output (ID₅₀, 100 µg/kg, s.c.). 6-oxo-PGF_{1a} had little effect on acid output in doses up to 50 μg⁻¹kg⁻¹min i.v. for 30 minutes. However, the stable prostacyclin analogue, PGI₁ inhibited acid secretion (ID₅₀, 4 μg kg⁻¹min⁻¹ i.v.) and in these antisecretory doses, it was less active than PGI₂ as a vasodepressor.

During the inhibition of acid secretion by PGI₂, the ratio of MBF to acid output increased. Furthermore, PGI₂ (0.5 µg⁻¹kg⁻¹min, i.v.) increased resting MBF, indicating a direct vasodilator action on the mucosa.

In the isolated perfused whole rat-stomach preparation (Bunce & Parsons, 1976), PGI₂ added to the serosal solution (pH 7.6, 37°C) inhibited histamine (5×10^{-5} M)-induced acid output with an ID₅₀ of 6×10^{-6} M. Although PGI₂ appeared less active than PGE₂ (ID₅₀, 10^{-6} M) in this preparation, this may well result from the rapid breakdown of PGI₂ under these

in vitro conditions; the stable analogue, PGI_1 , showed marked antisecretory activity (ID_{50} , 1.0×10^{-6} M).

The inhibition of gastric mucosal erosions was assessed 3 h after administration of indomethacin (20 mg/kg s.c.) as previously described (Whittle, 1976). Repeated subcutaneous administration of PGI₂, PGI₁ and 6-oxo-PGF_{1 α} reduced the incidence and severity of the lesions, with an ID₅₀ of 35, 30 and 500 µg kg⁻¹h⁻¹ respectively. Likewise, a single subcutaneous injection of PGI₂ and PGI₁ immediately prior to indomethacin, inhibited the erosions, with an ID₅₀ of 350 and 200 µg/kg s.c. respectively compared to 450 µg/kg s.c. for PGE₂. 6-oxo-PGF_{1 α} had little activity in single doses up to 500 µg/kg s.c.

The present findings indicate that prostacyclin exhibits many of the actions previously ascribed to PGE₂, being a potent mucosal vasodilator, an inhibitor of gastric acid secretion and an inhibitor of erosion formation in the rat. The interaction and relative roles of PGI₂ and PGE₂ in the gastric mucosa remains to be clarified.

References

BUNCE, K.T. & PARSONS, M.E. (1976). A quantitative study of metiamide, a histamine H₂-antagonist, on the isolated whole rat stomach. *J. Physiol.* (Lond.), 258, 453–465.

GRYGLEWSKI, R.J., BUNTING, S., MONCADA, S., FLOWER, R.J. & VANE, J.R. (1976). Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. *Prostaglandins*, 12, 685-713.

JOHNSON, R.A., LINCOLN, F.H., THOMPSON, J.L., NIDY, E.G., MIZSAK, S.A. & AXEN, U. (1977). Synthesis and stereochemistry of prostacyclin and synthesis of 6-keto prostaglandin F_{1a}. J. Am. Chem. Soc., 99, 3182-4184.

MAIN, I.H.M. & WHITTLE, B.J.R. (1973). The effects of E and A prostaglandins on gastric mucosal blood flow and acid secretion in the rat. *Br. J. Pharmac.*, 49, 428-436.

WHITTLE, B.J.R. (1976). Relationship between the prevention of rat gastric erosions and the inhibition of acid secretion by prostaglandins. *Eur. J. Pharmac.*, 40, 233-239.

The renal haemodynamic and excretory actions of prostacyclin (PGI₂) in anaesthetized dogs

T.W.K. HILL & S. MONCADA

Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS

Prostacyclin (PGI₂) is a newly discovered arachidonic acid metabolite synthesized in vascular walls of

different species including man. PGI₂ relaxes a variety of vascular muscle strips in vitro (Bunting, Gryglewski, Moncada & Vane, 1976) and is a strong hypotensive in rabbits and rats (Armstrong, Lattimer, Moncada & Vane, 1977).

As prostaglandins have profound stimulatory actions on renal haemodynamics and excretion in a variety of species (McGiff & Itskovitz, 1973) we have measured the renal actions of PGI₂ in anaesthetized dogs.

Anaesthesia was induced with thiopentone (30-40 mg/kg i.v.) and maintained with chloralose (25-35 mg/kg i.v.) and pentobarbitone (7.5-10.5 mg/kg i.v.). The dogs were artificially ventilated; arterial pO₂ was maintained above 90 mm Hg and pCO₂ in the range 25-40 mm Hg. A loading dose of creatinine (50 mg/kg in 0.9% w/v saline i.v.) was followed by a maintenance infusion (0.42 mg/kg⁻¹min⁻¹ in 0.9% saline at 0.25 ml/kg⁻¹min⁻¹) via a cannulated femoral vein. Arterial (BP) and venous (VP) blood pressures were measured from brachial vessels with pressure transducers connected to a chart recorder. Heart rate (HR) was recorded by integrating the arterial pulse. An electromagnetic flow probe (2-4 mm diameter) was fitted to the left renal artery to measure renal blood flow (RBF). The ureters were cannulated and urine flow (UV) from the left kidney recorded by integrating the signal from a photo-electric drop counter.

Renal arterial (i.a.) infusions of PGI_2 (30–300 ng/min for 15–30 min in 5 dogs) caused dose dependent increases in RBF, UV and sodium excretion ($U_{Na}V$), $U_{Cl}V$, $U_{Osm}V$, and reductions in calculated renal vascular resistance (RVR) and filtration fraction (FF) without altering BP or HR. Qualitatively similar responses to PGI_2 (1000–3000 ng/min i.a.) were associated with hypotension and tachycardia. VP and creatinine clearance (C_{Cr}) were unaffected.

Intravenous infusion of PGI_2 (30–300 ng/min in 3 dogs) tended to increase RBF but reduced $U_{Na}V$, $U_{Cl}V$, $U_{Osm}V$, while BP, HR, C_{CP} FF, UV and U_KV were unaltered. Larger doses (1000–3000 ng/min i.v.) caused pronounced hypotension accompanied by further elevations of RBF and HR, but reductions in

all other variables. The stable metabolite of prostacyclin, 6-oxo-PGF_{1 α} (10,000 ng/min) had no effect by either i.v. or i.a. routes.

After meclofenamate (2.5 mg/kg i.v. in 2 dogs), RBF was unchanged, though the increase in RBF to PGI₂ (300 ng/min i.a.) was enhanced.

As glomerular filtration rate ($C_{\rm Cr}$) was unaltered by sub-hypotensive doses (i.a.) of PGI₂, the reduction in calculated FF could be explained by efferent arteriolar dilatation (Bolger, Eisner, Ramwell & Slotkoff, 1976). Similarly, the increased $U_{\rm Na}V$ and $U_{\rm Cl}V$ resulted from reductions in tubular Na⁺ and Cl⁻ reabsorption, rather than through increases in their filtered loads. Endogenous PGI₂ synthesized by kidney vessels may influence renal function.

References

ARMSTRONG, J.M., LATTIMER, N., MONCADA, S. & VANE, J.R. (1977). Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin $F_{1\alpha}$ with those of prostaglandin E_2 in rats and rabbits. *Br. J. Pharmac*. (in press).

BOLGER, P.M., EISNER, G.M., RAMWELL, P.W. & SLOTKOFF, L.M. (1976). Effect of prostaglandin synthesis on renal function and renin in the dog. *Nature* (Lond.), 259, 244-245.

BUNTING, S., GRYGLEWSKI, R., MONCADA, S. & VANE, J.R. (1976). Arterial walls generate from prostaglandin endoperoxides a substance which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. *Prostaglandins*, 12, 897-913.

McGIFF, J.C. & ITSKOVITZ, H.D. (1973). Prostaglandins and the kidney. *Circulation Res.*, 33, 479–488.

Disappearance of prostacyclin (PGI₂) in the circulation of the dog

G.J. DUSTING, S. MONCADA & J.R. VANE

Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS

Prostacyclin (PGI₂) is a potent endogenous vasodilator in dogs (Armstrong, Chapple, Dusting, Hughes, Moncada & Vane, 1977a; Dusting, Moncada & Vane, 1977) rats and rabbits (Armstrong, Lattimer, Moncada & Vane, 1977b). Prostaglandin E₂ (PGE₂) is less potent as a hypotensive agent when given intravenously rather than intra-arterially because of extensive pulmonary metabolism (Ferreira & Vane, 1967), but prostacyclin is of similar potency when given by either route (Armstrong et al., 1977a, b). We have now examined the stability of prostacyclin in blood, and its removal by various vascular beds of the dog.

Prostacyclin was detected by direct bioassay in blood continuously withdrawn from the arterial cir-

culation of chloralose anaesthetized dogs (Vane, 1964). The vascular bioassay tissues (spiral strips of rabbit coeliac artery, RbCA; bovine coronary artery, BCA) were relaxed by prostacyclin (threshold 2–5 ng/ml), whereas gastro-intestinal bioassay tissues (rat stomach strip, RSS; rat colon, RC) were contracted by prostacyclin (threshold above 10 ng/ml). All bioassay tissues were insensitive to 6-oxo-PGF $_{1\alpha}$ (up to 100 ng/ml).

To measure the stability of prostacyclin in blood, a coil of silicone tubing was interposed between the blood supply and the bioassay tissues such that a transit time of up to 5 min could be achieved. Prostacyclin infusions (20–80 ng/ml) were made at different points in the coil and their effect compared with infusions of prostacyclin close to the assay tissues. From the disappearance of the activity on RbCA, BCA or RSS the half-life in blood was calculated to be 3.1 ± 0.4 min (6 experiments). This probably reflects chemical rather than enzymic breakdown for the half-life of prostacyclin in buffer at 37°C and pH 7.5 is about 3 minutes.